Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis

Abstract

IMPORTANCE Therapies that reduce psoriasis symptoms may improve work productivity. OBJECTIVE To assess the effect of ixekizumab therapy on work productivity, measured by the Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO). DESIGN, SETTING, AND PARTICIPANTS Three multicenter, randomized double-blind phase 3 trials conducted during the following periods:

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

“…In UNCOVER‐2, ixekizumab every 2 weeks was superior to etanercept (ETN) at 12 weeks in terms of PASI 75 (89.7% vs. 41.6%), the proportion of patients achieving a ≥90% improvement in PASI (PASI 90; 70.7% vs. 18.7%) and the proportion of patients achieving a 100% improvement in PASI (PASI 100; 40.5% vs. 5.3%); similar results were reported for UNCOVER‐3. Ixekizumab treatment has been reported to improve HRQoL as assessed by the DLQI, Itch Numeric Rating Scale (NRS) and Work Productivity Activity Impairment scale relative to patients treated with PBO or ETN . The objective of this study was to assess the speed of onset of ixekizumab‐induced clinically relevant improvement in DLQI and Itch NRS in an integrated database composed of patients who were randomized in UNCOVER‐2 and UNCOVER‐3.…”

Efficacy and safety of interleukin‐17 antagonists in patients with plaque psoriasis: a meta‐analysis from phase 3 randomized controlled trials

“…analysed two trials in one paper. One trial evaluated the effects of brodalumab, and four articles including three RCTs evaluated the effects of ixekizumab vs. placebo. The pooled analysis included 5951 patients with moderate‐to‐severe plaque psoriasis (4216 randomized to IL‐17 antagonists and 1735 to placebo).…”

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy

“…Furthermore, its efficacy has been confirmed also in difficult-to-treat areas (ie, scalp and nails)44–46 and severe clinical variants of psoriasis (ie, erythrodemic psoriasis) 41–43,45. Besides, ixekizumab has shown significant improvements in the activity of skin disease and in inhibiting radiographic progression in patients with concomitant iarthritis 46…”

“…The rapid onset of response determines a substantial gain in the patients’ quality of life and work productivity 40,44. Furthermore, its efficacy has been confirmed also in difficult-to-treat areas (ie, scalp and nails)44–46 and severe clinical variants of psoriasis (ie, erythrodemic psoriasis) 41–43,45.…”

“…In addition to classical efficacy measures, a revision of UNCOVER trials data by Armstrong et al described the effect of ixekizumab on work productivity, measured by the Work Productivity and Activity Impairment–Psoriasis (WPAI-PSO) 44. The WPAI-PSO questionnaire was administered at baseline, at week 12 and at weeks 24, 36, 52, and 60.…”